$19.1 Billion is the total value of Point72 Asset Management, L.P.'s 1298 reported holdings in Q2 2019. The portfolio turnover from Q1 2019 to Q2 2019 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| PIRS | PIERIS PHARMACEUTICALS INC | $1,606,000 | +40.3% | 341,667 | 0.0% | 0.01% | +60.0% | |
| TTOO | T2 BIOSYSTEMS INC | $1,008,000 | -36.1% | 600,000 | 0.0% | 0.01% | -28.6% | |
| MLND | MILLENDO THERAPEUTICS INC | $875,000 | -22.9% | 75,670 | 0.0% | 0.01% | 0.0% | |
| ONTX | ONCONOVA THERAPEUTICS INC | $689,000 | -13.7% | 241,850 | 0.0% | 0.00% | 0.0% | |
| EPHE | ISHARES TRmsci philips etf | $356,000 | +3.8% | 10,000 | 0.0% | 0.00% | 0.0% | |
| GREK | GLOBAL X FDSmsci greece etf | $287,000 | +19.1% | 30,000 | 0.0% | 0.00% | +100.0% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2019-08-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| SPDR S&P 500 ETF TR | 41 | Q2 2024 | 8.3% |
| CME GROUP INC | 41 | Q2 2024 | 0.3% |
| AMAZON COM INC | 39 | Q2 2024 | 3.2% |
| META PLATFORMS INC | 38 | Q1 2024 | 2.2% |
| XENON PHARMACEUTICALS INC | 38 | Q2 2024 | 0.4% |
| CSX CORP | 37 | Q2 2024 | 1.3% |
| BUNGE LIMITED | 37 | Q2 2023 | 1.5% |
| VULCAN MATLS CO | 37 | Q2 2024 | 0.9% |
| BERRY PLASTICS GROUP INC | 37 | Q1 2024 | 0.8% |
| GENERAL MTRS CO | 36 | Q2 2024 | 1.1% |
View Point72 Asset Management, L.P.'s complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Sphere Entertainment Co. | June 24, 2024 | 1,560,170 | 5.5% |
| UroGen Pharma Ltd. | June 24, 2024 | 2,569,826 | 6.2% |
| Olema Pharmaceuticals, Inc. | June 14, 2024 | 3,225,250 | 5.7% |
| MARAVAI LIFESCIENCES HOLDINGS, INC. | June 10, 2024 | 4,481,050 | 3.4% |
| Rapid7, Inc. | May 21, 2024 | 3,121,415 | 5.0% |
| Corvus Pharmaceuticals, Inc. | May 09, 2024 | 17,050,384 | 9.9% |
| Avid Bioservices, Inc. | April 26, 2024 | 3,226,006 | 5.1% |
| SUTRO BIOPHARMA, INC. | April 05, 2024 | 5,791,505 | 7.7% |
| Fox Corp | March 26, 2024 | 12,046,118 | 5.0% |
| LENZ Therapeutics, Inc. | March 25, 2024 | 864,942 | 3.4% |
View Point72 Asset Management, L.P.'s complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR/A | 2024-09-16 |
| SC 13G | 2024-09-05 |
| N-PX | 2024-09-03 |
| 13F-HR/A | 2024-08-19 |
| 13F-HR | 2024-08-14 |
| SC 13G | 2024-07-02 |
| SC 13G | 2024-06-24 |
| SC 13G | 2024-06-24 |
| SC 13G | 2024-06-14 |
| SC 13G | 2024-06-10 |
View Point72 Asset Management, L.P.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.